Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558994 | 0.83 | L3MBTL1 (0.52) | GRM5TYK2RORC | |
| SCHEMBL15205400 | 0.81 | GRM5 (0.44) | NPC1RAB9ASMN1; SMN2GRM5TYK2 | |
| SCHEMBL19958489 | 0.79 | RORC (0.49) | GRM5TYK2USP30GRM4BRAF | |
| SCHEMBL19151107 | 0.79 | TYK2 (0.50) | NPC1RAB9ASMN1; SMN2GRM5TYK2 | |
| SCHEMBL20909676 | 0.78 | NPC1 (0.63) | GCKNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL21766656 | 0.77 | NAMPT (0.47) | NPC1RAB9ASMN1; SMN2TP53RORC | |
| SCHEMBL3141770 | 0.77 | CDC7 (0.46) | SMN1; SMN2TYK2 | |
| SCHEMBL31703164 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2GRM5TYK2USP30GRM4 | |
| SCHEMBL24931494 | 0.76 | GSK3B (0.46) | MAP4K1GRM5TYK2USP30BRAF | |
| SCHEMBL16604288 | 0.76 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2GRM5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| EP-1807416-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655297-A1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | GCK 756/4885MAP4K1 193/4885NPC1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.